Research Topics
| Robert W DuboisSummaryAffiliation: Cerner Corporation Country: USA Publications
| Collaborators
|
Detail Information
Publications
Identification, diagnosis, and management of anemia in adult ambulatory patients treated by primary care physicians: evidence-based and consensus recommendationsRobert W Dubois
Cerner Health Insights, Beverly Hills, CA 90212, USA
Curr Med Res Opin 22:385-95. 2006..Provide recommendations for the identification, diagnosis, and management of ambulatory patients with anemia...- Geographic variation in the use of medications: is uniformity good news or bad?Robert W Dubois
Zynx Health, Beverly Hills, California, USA
Health Aff (Millwood) 21:240-50. 2002..To determine whether these findings represent good or bad news will require further study... - Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapyR W Dubois
Zynx Health Inc, Beverly Hills, CA 90212, USA
Aliment Pharmacol Ther 19:197-208. 2004..To rationalize decision making around the use of different non-steroidal anti-inflammatory drug (NSAID) treatment strategies in patients with varying degrees of gastrointestinal and cardiovascular risk... 
The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UKZhimei Liu
Cerner LifeSciences, Beverly Hills, California, USA
Appl Health Econ Health Policy 7:193-205. 2009..Once-per-cycle pegfilgrastim and daily filgrastim are two commonly used G-CSFs with different dosing schedules and associated costs...- Growth in use of lipid-lowering therapies: are we targeting the right patients?Robert W Dubois
Zynx Health, Inc, Beverly Hills, California 90212, USA
Am J Manag Care 8:862-7. 2002..Concern exists that industry marketing has led to increased use of medications by patients with marginal indications... - Evolution of clinical practice guidelines: evidence supporting expanded use of medicinesRobert W Dubois
Cerner LifeSciences, Beverly Hills, California 90212, USA
Dis Manag 9:210-23. 2006..These trends are likely to continue with important economic, clinical, and policy ramifications... - Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed populationQuan V Doan
Cerner LifeSciences, Beverly Hills, CA, USA
J Med Econ 11:23-40. 2008..This study aimed to evaluate the economic impact of treating GERD with PPIs versus no treatment, from an employer's perspective... - Economic burden of cardiovascular events and fractures among patients with end-stage renal diseaseQuan V Doan
Cerner LifeSciences, 9100 Wilshire Blvd, Suite 655E, Beverly Hills, CA 90212, USA
Curr Med Res Opin 23:1561-9. 2007..To quantify direct medical costs of fractures and cardiovascular diseases among end-stage renal disease (ESRD) patients... - A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleedingZhimei Liu
Cerner LifeSciences, 9100 Wilshire Boulevard, Beverly Hills, CA 90212, USA
Value Health 10:183-94. 2007..To date, this burden has not been systematically studied. We conducted a systematic review of the medical literature to evaluate the impact of AUB on HRQoL and to quantify the economic burden of AUB from a societal perspective... - The relationship between the prevalence of nighttime gastroesophageal reflux disease and disease severityBonnie B Dean
Cerner LifeSciences, 9100 Wilshire Blvd, Suite 655 East Tower, Beverly Hills, CA, 90212, USA
Dig Dis Sci 55:952-9. 2010..Nighttime gastrointestinal reflux disease (GERD) prevalence and severity estimates vary substantially across studies... - Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulinKelly J Ko
Cerner LifeSciences, Beverly Hills, California, USA
Clin Ther 32:1954-66. 2010..Research suggests that analogue bolus insulin may be more effective in achieving blood glucose (BG) control compared with human bolus insulin... - Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritisQuan V Doan
Cerner LifeSciences, 9100 Wilshire Blvd, Suite 605E, Beverly Hills, CA 90212, USA
J Manag Care Pharm 12:555-69. 2006..Treatment options for the management of rheumatoid arthritis (RA) have expanded from the traditional disease-modifying antirheumatic drugs (DMARDs) to include the biologic DMARDs that inhibit tumor necrosis factoralpha (TNF-a)... - Outpatient cancer drug costs: changes, drivers, and the futureR J Halbert
Protocare Sciences, Inc, Santa Monica, California 90404, USA
Cancer 94:1142-50. 2002..To the authors' knowledge, no analysis has examined the specific components of drug spending for overall cancer care. The authors' objective was to quantify and characterize trends in outpatient drug expenditures for cancer patients... - Economic and clinical impact of inpatient diabetic hypoglycemiaSuellen M Curkendall
Cerner LifeSciences, Beverly Hills, California 90212, USA
Endocr Pract 15:302-12. 2009..To assess the clinical and economic impact of hypoglycemia that develops during hospitalization of patients with diabetes... - Pharmaceutical promotion: don't throw the baby out with the bathwaterRobert W Dubois
Zynx Health Inc, Beverly Hills, California, USA
Health Aff (Millwood) . 2003.... - Development and validation of a case ascertainment tool for ankylosing spondylitisMichael H Weisman
Cedars Sinai Medical Center, Los Angeles, California, USA
Arthritis Care Res (Hoboken) 62:19-27. 2010..We tested questions derived from a comprehensive literature review and an advisory board in a case-control study designed to identify patients with AS from among patients with chronic back pain (CBP)... - Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness PanelRonald J Halbert
Cerner Life Sciences, Beverley Hills, California, USA
Cancer 107:2375-83. 2006..The authors convened a panel of medical and urologic oncologists to rate the appropriateness of the main options... - Septicemia in patients with ESRD is associated with decreased hematocrit and increased use of erythropoietinAllen R Nissenson
David Geffen School of Medicine, University of California Los Angeles, 200 UCLA Medical Plaza, Suite 565 57, Los Angeles, CA 90095, USA
Clin J Am Soc Nephrol 1:505-10. 2006..Strategies to prevent septicemia are important not only to decrease clinical morbidity but also to conserve EPO usage and thus contain the costs of care for this complex patient population... - Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysisAllen R Nissenson
David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Am J Kidney Dis 46:301-8. 2005..CONCLUSION: Patients with septicemia caused by S aureus had costly and lengthy hospitalizations, which frequently were associated with clinically and economically important complications, including hospital readmissions... - Economic burden of anemia in an insured populationAllen R Nissenson
Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, 90095 6945, USA
J Manag Care Pharm 11:565-74. 2005..This study examines anemia prevalence and associated medical costs and utilization, using administrative claims for adults newly diagnosed with anemia, including up to 12 months of follow-up... - Anemia: not just an innocent bystander?Allen R Nissenson
Arch Intern Med 163:1400-4. 2003 - Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysisFranz H Messerli
Division of Cardiology, St Luke s Roosevelt Hospital, New York, New York, USA
Am J Cardiol 101:319-25. 2008..51, p=0.22). In conclusion, statin therapy effectively decreases CV morbidity and mortality to the same extent in hypertensive and nonhypertensive patients... - When is it appropriate to prescribe postmenopausal hormone therapy?Bruce Ettinger
University of California, San Francisco, San Francisco, CA, USA
Menopause 13:404-10. 2006..To develop evidence and consensus-based recommendations for the use of hormone therapy (HT) in postmenopausal women... - Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraceptionPaul D Blumenthal
Department of Gynecology and Obstetrics, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
Contraception 74:249-58. 2006..5% with OCs and 34% with the LNG-IUS at 12 months. CONCLUSIONS: Treatment strategies employing the LNG-IUS are the most cost-effective in managing DUB, regardless of whether a woman has previously tried OC therapy...